ABSTRACT
Objectives: To evaluate the clinical efficacy of highly agglutinative staphylococcin combined with neoadjuvant chemotherapy on patients with intermediate or advanced oral cancer. Methods: A total of 80 patients with intermediate or advanced oral cancer treated in Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine from January 2020 to January 2022 were included. Patients were divided into two groups based on their treatment choice, with 40 cases in each group. Patients in the control group were given paclitaxel combined with cisplatin chemotherapy regimen: paclitaxel 150 mg/m2 and cisplatin 100 mg/m2 on Day-1, with 28 days as one cycle of chemotherapy for a total of three cycles. Patients in the experimental group received intramuscular injection of 500U highly agglutinative staphylococcin once a day for two weeks on the basis of chemotherapy, and continued the next course of treatment after 1 week of withdrawal, with a total of two courses. After treatment, the therapeutic effect, adverse drug reactions, changes in tumor markers such as CEA, NSE, CA19-9 and CA125 before and after treatment, as well as differences in levels of CD3+, CD4+, CD8+ and CD4+/CD8+ of T lymphocyte subsets between the two groups before and after treatment were compared and analyzed. Results: The total efficacy of the experimental group was 80%, which was significantly better than 57.5% of the control group (P=0.03). The incidence of adverse drug reactions in the experimental group was 17.5%, while that in the control group was 42.5%, showing a statistically significant difference (P=0.02), and the WBC count decreased more significantly in the control group (P=0.04). CEA, NSE, CA19-9 and CA125 decreased significantly in the experimental group after treatment compared with the control group, with a statistically significant difference (P=0.00). Moreover, the levels of CD3+, CD4+, CD4+/CD8+ in the experimental group after treatment were significantly higher than those in the control group, with statistically significant differences (CD3+, P=0.03; CD4+, P=0.00; CD4+/CD8+, P=0.00), while CD8+ did not change significantly (P=0.95). Conclusions: Highly agglutinative staphylococcin combined with chemotherapy is a safe and effective treatment regimen with definite curative effect for patients with intermediate or advanced oral cancer. With such a regimen, tumor markers are remarkably reduced, immune function can be significantly improved, and adverse reactions will be evidently reduced.
ABSTRACT
Objective:To observe the clinical efficacy and side effects of highly agglutinative staphylococcin injection at high dose combined with oxaliplatin or cisplatin with intraperitoneal perfusion in the treatment of malignant peritoneal effusion. Methods:Totally 60 patients with malignant peritoneal effusion were divided into two groups,32 cases in group A,and 28 cases in group B. Group A was treated with staphylococcin at high dose combined with oxaliplatin with intraperitoneal infusion after peritoneal cavity catheter drainage,and group B was treated with staphylococcin at high dose combined with cisplatin with intraperitoneal infusion after peritoneal cavity catheter drainage. All patients underwent the treatment once a week,and continuous four weeks for a courese. The clinical efficacy and adverse drug reactions were compared between the two groups. Results:The complete response rate of group A was 18. 8% ,and the total effective rate was 90. 7% ,which were both significantly higher than those of group B(P 0. 05). Conclusion:Staphylococcin at high dose combined with oxaliplatin with intraperitoneal perfusion is more effective than staphylococcin at high dose combined with cisplatin. Although abdominal pain in group A is obvious,the patients are able to tolerate with it after the symptomatic treatment,therefore,staphylococcin at high dose combined with oxaliplatin with intraperitoneal perfusion can be used as one of effective methods for the treatment of malignant peritoneal effusion.
ABSTRACT
Objective To summarize the nursing experience of combination therapy of highly agglutinative staphylococcin (HASL) with cisplatin for patients with malignant pleural effusions. Methods After fully draining of pleural fluid in 62 cases with malignant pleural effusion through pleural puncture through central venous catheters and simply suction bottles, we injected HASL and cisplatin into the patients' pleural cavities. During the therapeutic process, firstly, we drained the pleural fluid fully before injection, secondly, we directed the patients to cooperate well and alter the positions properly, and thirdly, we closely observed the patients' condition and adverse reactions. Results 54 of 62 cases were effective after the therapies. The effective rate was 87.1%.Conclusions In order to achieve a satisfled curative effect and reduce the adverse reactions, we need the cooperation of the patients, fully draining of the pleural fluid before injection and proper alternation of the patients' positions during the treatment process.
ABSTRACT
OBJECTIVE: To observe the clinical efficacy of highly agglutinative staphylococcin (HAS) combined with cisplatin in the treatment of malignant hydrothorax after straining and inserting central venous catheter in thoracic cavity. METHODS: 90 patients with malignant hydrothorax combined with lung cancer were randomly divided into A、B、C 3 groups. Central venous catheter was inserted in thoracic cavity for strainage. Group A were intrapleural injected with 5 000 U HAS, group B 40 mg?m-2 cisplatin and group C 5 000 U HAS combined with 40 mg?m-2 cisplatin once a week. Clinical efficacies of 3 groups were evaluated after 3 weeks of treatment. RESULTS: The total effective rate of group A, B and C were 43.0%, 46.7% and 80.0% respectively. There was obvious difference between group C and A as well as group B(P
